Opportunity Information: Apply for PAR 21 191
The National Institutes of Health (NIH) funding opportunity titled "Firearm Injury and Mortality Prevention Research (R21/R33 Clinical Trial Optional)" (Funding Opportunity Number PAR-21-191) supports research aimed at reducing firearm-related injuries and deaths in the United States. The opportunity is grounded in the reality that close to 40,000 people in the U.S. die each year from firearm-related causes, with the majority of deaths attributed to suicide (about 60 percent) and a large share to homicide (about 37 percent). Beyond fatalities, NIH highlights that many more people experience non-fatal firearm injuries, including both intentional and unintentional incidents, underscoring a broad public health burden that extends well past mortality statistics.
This program stems from direction and funding included in the Consolidated Appropriations Act, 2021 (Public Law 116-260), where accompanying legislative language recommended that NIH take a comprehensive approach to studying both the underlying causes of firearm injury and the evidence-based ways to prevent it. Importantly, the scope of work is framed within specific legislative mandates and limitations on NIH funding, referenced in NIH notices NOT-OD-21-058 and NOT-OD-21-056. Within those boundaries, NIH is encouraging research that can build practical, evidence-driven knowledge about why firearm injuries occur, who is most at risk, and what strategies can reliably prevent harm.
The research priorities emphasized in the announcement fall into several connected areas. First, NIH seeks studies that improve understanding of the determinants of firearm injury, meaning the individual, social, environmental, and systemic factors that increase or decrease risk. Second, the opportunity prioritizes research that improves identification of people at risk of firearm injury, explicitly including both potential victims and potential perpetrators, reflecting an interest in prevention strategies that address multiple pathways to harm. Third, NIH encourages the development and early testing (piloting) of innovative interventions designed to prevent firearm injury and mortality, which can include new approaches in clinical, community, educational, or policy-adjacent settings as long as they fit NIH rules. Fourth, there is a strong implementation focus: applicants are encouraged to study how to improve the delivery, uptake, and real-world impact of existing evidence-based interventions, recognizing that proven strategies do not automatically translate into consistent practice or equitable outcomes.
Mechanistically, the funding uses an R21/R33 structure and is labeled "Clinical Trial Optional." In general terms, that means proposals may include a clinical trial if it is appropriate for the research question, but a clinical trial is not required. The R21/R33 design is commonly used to support exploratory or early-stage work (R21) that can transition into a second phase (R33) if initial milestones are met, making it a fit for projects that begin with feasibility testing, intervention refinement, or proof-of-concept and then expand into more rigorous evaluation.
Eligibility is broad and spans many types of U.S.-based organizations. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled colleges and universities; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those nonprofit categories); for-profit organizations (other than small businesses); small businesses; and other qualifying entities. The announcement also calls out additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
At the same time, the opportunity clearly restricts foreign involvement in the application structure. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. In other words, this is intended to be carried out through U.S.-based applicant organizations without foreign components.
The opportunity is categorized as a discretionary grant under NIH and falls under broad public service areas including education, health, and social services. It lists multiple CFDA numbers (93.213, 93.273, 93.279, 93.307, 93.313, 93.865, 93.866), reflecting that multiple NIH institutes or program lines may be involved in supporting or administering related research areas. The original closing date shown is April 30, 2021, and the source data does not specify an award ceiling or the expected number of awards, which typically means applicants would need to consult the full funding announcement or NIH institute guidance for budget expectations and programmatic fit.
Overall, the grant opportunity is designed to grow the evidence base around firearm injury and mortality prevention by supporting studies that clarify risk and protective factors, improve risk identification for both victims and perpetrators, create and pilot new preventive interventions, and strengthen how proven interventions are implemented in real-world settings, all while operating within NIH statutory and policy constraints.Apply for PAR 21 191
- The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "Firearm Injury and Mortality Prevention Research (R21/R33 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.273, 93.279, 93.307, 93.313, 93.865, 93.866.
- This funding opportunity was created on 2021-03-05.
- Applicants must submit their applications by 2021-04-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this NIH grant?
The funding opportunity is titled "Firearm Injury and Mortality Prevention Research (R21/R33 Clinical Trial Optional)" and the Funding Opportunity Number is PAR-21-191.
What is the main goal of this funding opportunity?
The goal is to support research that can help reduce firearm-related injuries and deaths in the United States by building practical, evidence-driven knowledge about why firearm injuries occur, who is most at risk, and what strategies can reliably prevent harm.
Why is NIH supporting research in this area?
NIH frames this opportunity around a major public health burden in the U.S., noting that close to 40,000 people die each year from firearm-related causes and that many more experience non-fatal firearm injuries (intentional and unintentional). The program also stems from direction and funding included in the Consolidated Appropriations Act, 2021 (Public Law 116-260), which recommended a comprehensive approach to studying both underlying causes and evidence-based prevention.
What firearm-related outcomes does NIH emphasize in the description?
The description emphasizes both mortality and non-fatal injuries. For deaths, it highlights that the majority are attributed to suicide (about 60 percent) and a substantial share to homicide (about 37 percent). It also stresses that non-fatal firearm injuries add to the broader burden beyond mortality statistics.
What kinds of research topics or priorities are highlighted?
The announcement emphasizes several connected priorities:
- Improving understanding of the determinants of firearm injury (individual, social, environmental, and systemic factors).
- Improving identification of people at risk of firearm injury, including both potential victims and potential perpetrators.
- Developing and piloting innovative interventions to prevent firearm injury and mortality (in settings such as clinical, community, educational, or policy-adjacent contexts, as permitted by NIH rules).
- Studying implementation to improve delivery, uptake, and real-world impact of existing evidence-based interventions.
What does "determinants of firearm injury" mean in this opportunity?
In this context, determinants refer to the factors that can increase or decrease risk of firearm injury, including individual-level factors and broader social, environmental, and systemic influences.
Does the opportunity support research focused on people who may perpetrate firearm violence, not only victims?
Yes. The priorities explicitly include improving identification of people at risk, including both potential victims and potential perpetrators, reflecting an interest in prevention strategies that address multiple pathways to harm.
Are intervention studies encouraged, or is this limited to observational research?
Intervention work is encouraged. The opportunity highlights the development and early testing (piloting) of innovative interventions, and it also emphasizes implementation research to improve how existing evidence-based interventions are delivered and adopted in real-world settings.
What does "implementation focus" mean here?
It refers to studying how to improve the delivery, uptake, and real-world impact of interventions that already have evidence supporting them, recognizing that proven strategies may not automatically translate into consistent practice or equitable outcomes.
What funding mechanism is used (R21/R33), and what does that imply?
The opportunity uses an R21/R33 structure. In general terms, this structure supports exploratory or early-stage work in an initial phase (R21) that can transition into a second phase (R33) if initial milestones are met. It is often suited for projects that start with feasibility testing, intervention refinement, or proof-of-concept work and then expand into more rigorous evaluation.
Is a clinical trial required?
No. The announcement is labeled "Clinical Trial Optional," meaning a clinical trial may be included if appropriate to the research question, but it is not required.
What types of organizations are eligible to apply?
Eligibility is broad and includes many U.S.-based organizations, such as:
- State, county, city or township, and special district governments
- Independent school districts
- Public and state-controlled colleges and universities
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Tribal organizations other than federally recognized governments
- Public housing authorities and Indian housing authorities
- Nonprofits with or without 501(c)(3) status (excluding higher education institutions in those nonprofit categories)
- For-profit organizations (other than small businesses)
- Small businesses
- Other qualifying entities
Are minority-serving institutions and community-based organizations specifically mentioned as eligible?
Yes. The announcement calls out additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs). It also mentions faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Are non-U.S. (foreign) organizations allowed to apply?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply.
Can a U.S. organization include a non-domestic component or foreign component in the project?
No. The opportunity states that non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What legislation and NIH notices are referenced as shaping the scope and limitations of this work?
The program is described as stemming from direction and funding included in the Consolidated Appropriations Act, 2021 (Public Law 116-260). It also references NIH notices NOT-OD-21-058 and NOT-OD-21-056 regarding legislative mandates and limitations on NIH funding.
What general program area does this opportunity fall under?
It is described as a discretionary NIH grant and is associated with broad public service areas including education, health, and social services.
What CFDA numbers are associated with this funding opportunity?
The opportunity lists multiple CFDA numbers: 93.213, 93.273, 93.279, 93.307, 93.313, 93.865, and 93.866. This suggests multiple NIH institutes or program lines may be involved in supporting or administering related research areas.
What was the closing date shown for this opportunity?
The original closing date shown is April 30, 2021.
Does the provided information include an award ceiling or the expected number of awards?
No. The source information provided does not specify an award ceiling or the expected number of awards. In cases like this, applicants typically need to consult the full funding announcement or relevant NIH institute guidance for budget expectations and fit.
What kinds of settings can interventions be developed or tested in under this opportunity?
The description notes that innovative interventions can be developed and piloted in settings such as clinical, community, educational, or policy-adjacent settings, as long as they fit NIH rules and the stated constraints of the opportunity.
Does this opportunity only focus on fatal firearm events?
No. While mortality is a major focus, NIH also emphasizes the large number of non-fatal firearm injuries (intentional and unintentional) as part of the overall burden.
What is the overall approach NIH is encouraging through this program?
Within the stated statutory and policy constraints, NIH is encouraging a comprehensive, evidence-driven approach that (1) clarifies risk and protective factors, (2) improves identification of who is most at risk (including potential victims and perpetrators), (3) creates and pilots new preventive interventions, and (4) strengthens implementation of proven interventions in real-world settings.
Browse more opportunities from the same category: Education, Health, Income Security and Social Services
Next opportunity: Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
Previous opportunity: Frontier Health Markets APS
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 191
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 191) also looked into and applied for these:
| Funding Opportunity |
|---|
| BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 135 Funding Number: RFA MH 21 135 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Apply for PAR 21 163 Funding Number: PAR 21 163 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 130 Funding Number: RFA MH 21 130 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) Apply for PAR 21 162 Funding Number: PAR 21 162 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional) Apply for RFA AI 21 018 Funding Number: RFA AI 21 018 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) Apply for RFA MH 21 180 Funding Number: RFA MH 21 180 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) Apply for PAR 21 233 Funding Number: PAR 21 233 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) Apply for RFA MH 21 175 Funding Number: RFA MH 21 175 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) Apply for RFA NS 21 023 Funding Number: RFA NS 21 023 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $1,000,000 |
| BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) Apply for RFA NS 21 024 Funding Number: RFA NS 21 024 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $1,500,000 |
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required) Apply for PAR 21 154 Funding Number: PAR 21 154 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) Apply for RFA NS 21 027 Funding Number: RFA NS 21 027 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) Apply for RFA NS 21 026 Funding Number: RFA NS 21 026 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Clinical Trials Not Allowed) Apply for PAR 21 281 Funding Number: PAR 21 281 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 - Basic Experimental Studies with Humans) Apply for PAR 21 280 Funding Number: PAR 21 280 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) Apply for RFA MH 21 205 Funding Number: RFA MH 21 205 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (U01 Clinical Trial Not Allowed) Apply for RFA MH 21 236 Funding Number: RFA MH 21 236 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases (UM1 Clinical Trial Not Allowed) Apply for RFA MH 21 235 Funding Number: RFA MH 21 235 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (U24 Clinical Trial Not Allowed) Apply for RFA MH 21 237 Funding Number: RFA MH 21 237 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional) Apply for RFA AI 21 058 Funding Number: RFA AI 21 058 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 191", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.